Sumitomo Mitsui DS Asset Management Company Ltd Has $1.30 Million Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 48.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,798 shares of the biopharmaceutical company's stock after purchasing an additional 13,615 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Royalty Pharma were worth $1,301,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Louisbourg Investments Inc. acquired a new position in shares of Royalty Pharma during the 1st quarter worth approximately $28,000. MassMutual Private Wealth & Trust FSB grew its position in shares of Royalty Pharma by 76.4% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 414 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 1,003 shares in the last quarter. Westpac Banking Corp acquired a new position in shares of Royalty Pharma during the 4th quarter worth approximately $53,000. Finally, National Bank of Canada FI grew its position in shares of Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 371 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on RPRX shares. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Morgan Stanley assumed coverage on shares of Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target for the company. Finally, Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $47.33.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded up $0.14 on Friday, reaching $36.33. 1,196,661 shares of the stock were exchanged, compared to its average volume of 3,679,527. The firm's 50 day moving average is $33.88 and its 200-day moving average is $31.98. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $36.43. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.56 and a current ratio of 1.56. The firm has a market cap of $20.42 billion, a PE ratio of 19.64, a P/E/G ratio of 1.87 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. As a group, analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.